<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03147313</url>
  </required_header>
  <id_info>
    <org_study_id>MPG 07/2016</org_study_id>
    <nct_id>NCT03147313</nct_id>
  </id_info>
  <brief_title>Extracorporal Shock Wave Treatment to Improve Nerve Regeneration</brief_title>
  <official_title>Extracorporal Shock Wave Treatment After Microsurgical Coaptation to Improve Nerve Regeneration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ludwig Boltzmann Gesellschaft</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ludwig Boltzmann Gesellschaft</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the impact of extracorporeal shock wave treatment after microsurgical
      coaptation of finger nerves. Participants will be randomized into two treatment groups with
      different settings and a sham group. The participants will thereafter followed-up in a
      prospective, double-blind study design.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Extracorporeal shock wave treatment is CE certified in Austria, Europe and licensed for
      indications like achillodynia, epicondylitis, or tendinitis calcanea. The Orthogold 100
      device by MTS Medical UG will be used for this study.

      Defocused low-energy extracorporeal shock wave therapy (ESWT) has gained acceptance as a
      therapeutic tool in different medical settings. It has been shown, that shock waves stimulate
      of the metabolic activity of different cell type, including osteoblasts, tenocytes,
      endothelial cells and chondrocytes. Furthermore, it has proved effective in clinical
      applications relating to bone and wound healing and myocardial ischaemia. Until now, no
      studies have been performed regarding the effects of ESWT on regeneration of peripheral nerve
      injuries in humans.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 18, 2017</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Anticipated">April 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Participants will be randomized into three groups: Two treatment groups with different treatment settings and one sham group.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
    <masking_description>The participant will be wearing an acoustic and visual masking. The outcome assessor won't know if the participant was treated or if he was assigned to the sham group.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Two Point Discrimination</measure>
    <time_frame>1 year</time_frame>
    <description>Two Point Discrimination distal of the nerve lesion in mm</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Semmes Weinstein Monofilament test</measure>
    <time_frame>1 year</time_frame>
    <description>Palpable Monofilaments, measured in Newton</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pain/Discomfort</measure>
    <time_frame>1 year</time_frame>
    <description>0=Hinders function 1=Disturbing 2=Moderate 3=None/minor</description>
  </primary_outcome>
  <primary_outcome>
    <measure>hyperesthesia</measure>
    <time_frame>1 year</time_frame>
    <description>0=Hinders function 1=Disturbing 2=Moderate 3=None/minor</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tinel Hoffmann sign</measure>
    <time_frame>1 year</time_frame>
    <description>Progression of TH sign into the periphery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sonography</measure>
    <time_frame>1 year</time_frame>
    <description>sonography of the coaptation neuroma, measurement of the maximum diameter in mm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>velocity of nerve conduction</measure>
    <time_frame>1 year</time_frame>
    <description>Determination of velocity of nerve conduction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medical Research Council Grading of Sensibility</measure>
    <time_frame>1 year</time_frame>
    <description>Grading by the british medical research council. S0: No recovery of sensibility S1: Deep cutaneous pain sensibility S1+: superficial pain sensibility S2: superficial pain and some touch sensibility S2+: As in S2 but with overresponse S3: Pain and touch sensibility with over response, 2PD &gt; 15mm S3+: As S3 but with imperfect recovery of 2PD (7-15mm) S4: Complete recovery</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Peripheral Nerve Injury</condition>
  <arm_group>
    <arm_group_label>Sham</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Shockwave 300 pulses</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>300 pulses of extracorporeal shock wave will be applied</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Shockwave 500 pulses</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>500 pulses of extracorporeal shock wave will be applied</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MTS Medical UG Orthogold 100</intervention_name>
    <description>300 or 500 pulses, frequency 3Hz, energy 1 (0,1mJ/mm2)</description>
    <arm_group_label>Shockwave 300 pulses</arm_group_label>
    <arm_group_label>Shockwave 500 pulses</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sham</intervention_name>
    <description>Extracorporeal shock wave treatment will be faked.</description>
    <arm_group_label>Sham</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  complete lossless transection of one or more digital nerves distal to the branching
             out of the commune median or ulnar nerves

          -  direct, tension-free coaptation of the nerve stumps

        Exclusion Criteria:

          -  segment loss of the nerve

          -  tension after direct coaptation

          -  diabetic neuropathy or other peripheral neuropathies

          -  other disease with reduced sensibility of the fingers

          -  injuries in the course of the nerve (plexus brachialis, median or ulnar nerve)

          -  chronic inflammatory disease

          -  rheumatoid arthritis

          -  pregnancy

          -  patients not able to give written consent

          -  patients with an implantable cardiac defibrillator or pacemaker

          -  patients which are sensitive to electromagnetic radiance
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Rudolf Rosenauer, M.D.</last_name>
    <phone>0043 59393 41270</phone>
    <email>rudolf.rosenauer@auva.at</email>
  </overall_contact>
  <location>
    <facility>
      <name>Meidling Trauma Hospital</name>
      <address>
        <city>Vienna</city>
        <zip>1120</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rainer Mittermayr, M.D.</last_name>
      <phone>0043 5 939345263</phone>
      <email>rainer.mittermayr@auva.at</email>
    </contact>
    <investigator>
      <last_name>Rainer Mittermayr, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lorenz Böhler Trauma Hospital</name>
      <address>
        <city>Vienna</city>
        <zip>1200</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rudolf Rosenauer, M.D.</last_name>
      <phone>0043 59393 41270</phone>
      <email>rudolf.rosenauer@auva.at</email>
    </contact>
    <contact_backup>
      <last_name>Stefan Quadlbauer, M.D.</last_name>
      <phone>0043 59393 41000</phone>
      <email>stefan.quadlbauer@auva.at</email>
    </contact_backup>
    <investigator>
      <last_name>Rudolf Rosenauer, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stefan Quadlbauer, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <reference>
    <citation>Bosch G, Lin YL, van Schie HT, van De Lest CH, Barneveld A, van Weeren PR. Effect of extracorporeal shock wave therapy on the biochemical composition and metabolic activity of tenocytes in normal tendinous structures in ponies. Equine Vet J. 2007 May;39(3):226-31.</citation>
    <PMID>17520973</PMID>
  </reference>
  <reference>
    <citation>Corson MA, James NL, Latta SE, Nerem RM, Berk BC, Harrison DG. Phosphorylation of endothelial nitric oxide synthase in response to fluid shear stress. Circ Res. 1996 Nov;79(5):984-91.</citation>
    <PMID>8888690</PMID>
  </reference>
  <reference>
    <citation>Fleming I, Bauersachs J, Fisslthaler B, Busse R. Ca2+-independent activation of the endothelial nitric oxide synthase in response to tyrosine phosphatase inhibitors and fluid shear stress. Circ Res. 1998 Apr 6;82(6):686-95.</citation>
    <PMID>9546377</PMID>
  </reference>
  <reference>
    <citation>Fukumoto Y, Ito A, Uwatoku T, Matoba T, Kishi T, Tanaka H, Takeshita A, Sunagawa K, Shimokawa H. Extracorporeal cardiac shock wave therapy ameliorates myocardial ischemia in patients with severe coronary artery disease. Coron Artery Dis. 2006 Feb;17(1):63-70.</citation>
    <PMID>16374144</PMID>
  </reference>
  <reference>
    <citation>Hausdorf J, Sievers B, Schmitt-Sody M, Jansson V, Maier M, Mayer-Wagner S. Stimulation of bone growth factor synthesis in human osteoblasts and fibroblasts after extracorporeal shock wave application. Arch Orthop Trauma Surg. 2011 Mar;131(3):303-9. doi: 10.1007/s00402-010-1166-4. Epub 2010 Aug 22.</citation>
    <PMID>20730589</PMID>
  </reference>
  <reference>
    <citation>Martini L, Giavaresi G, Fini M, Torricelli P, de Pretto M, Schaden W, Giardino R. Effect of extracorporeal shock wave therapy on osteoblastlike cells. Clin Orthop Relat Res. 2003 Aug;(413):269-80.</citation>
    <PMID>12897619</PMID>
  </reference>
  <reference>
    <citation>Moretti B, Notarnicola A, Garofalo R, Moretti L, Patella S, Marlinghaus E, Patella V. Shock waves in the treatment of stress fractures. Ultrasound Med Biol. 2009 Jun;35(6):1042-9. doi: 10.1016/j.ultrasmedbio.2008.12.002. Epub 2009 Feb 25.</citation>
    <PMID>19243882</PMID>
  </reference>
  <reference>
    <citation>Moretti B, Notarnicola A, Maggio G, Moretti L, Pascone M, Tafuri S, Patella V. The management of neuropathic ulcers of the foot in diabetes by shock wave therapy. BMC Musculoskelet Disord. 2009 May 27;10:54. doi: 10.1186/1471-2474-10-54.</citation>
    <PMID>19473538</PMID>
  </reference>
  <reference>
    <citation>Murata R, Nakagawa K, Ohtori S, Ochiai N, Arai M, Saisu T, Sasho T, Takahashi K, Moriya H. The effects of radial shock waves on gene transfer in rabbit chondrocytes in vitro. Osteoarthritis Cartilage. 2007 Nov;15(11):1275-82. Epub 2007 May 29.</citation>
    <PMID>17537650</PMID>
  </reference>
  <reference>
    <citation>Nishida T, Shimokawa H, Oi K, Tatewaki H, Uwatoku T, Abe K, Matsumoto Y, Kajihara N, Eto M, Matsuda T, Yasui H, Takeshita A, Sunagawa K. Extracorporeal cardiac shock wave therapy markedly ameliorates ischemia-induced myocardial dysfunction in pigs in vivo. Circulation. 2004 Nov 9;110(19):3055-61. Epub 2004 Nov 1.</citation>
    <PMID>15520304</PMID>
  </reference>
  <reference>
    <citation>Schaden W, Fischer A, Sailler A. Extracorporeal shock wave therapy of nonunion or delayed osseous union. Clin Orthop Relat Res. 2001 Jun;(387):90-4.</citation>
    <PMID>11400900</PMID>
  </reference>
  <reference>
    <citation>Schaden W, Thiele R, Kölpl C, Pusch M, Nissan A, Attinger CE, Maniscalco-Theberge ME, Peoples GE, Elster EA, Stojadinovic A. Shock wave therapy for acute and chronic soft tissue wounds: a feasibility study. J Surg Res. 2007 Nov;143(1):1-12. Epub 2007 Sep 27.</citation>
    <PMID>17904157</PMID>
  </reference>
  <reference>
    <citation>Zimpfer D, Aharinejad S, Holfeld J, Thomas A, Dumfarth J, Rosenhek R, Czerny M, Schaden W, Gmeiner M, Wolner E, Grimm M. Direct epicardial shock wave therapy improves ventricular function and induces angiogenesis in ischemic heart failure. J Thorac Cardiovasc Surg. 2009 Apr;137(4):963-70. doi: 10.1016/j.jtcvs.2008.11.006.</citation>
    <PMID>19327525</PMID>
  </reference>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 21, 2017</study_first_submitted>
  <study_first_submitted_qc>May 9, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 10, 2017</study_first_posted>
  <last_update_submitted>May 9, 2017</last_update_submitted>
  <last_update_submitted_qc>May 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ludwig Boltzmann Gesellschaft</investigator_affiliation>
    <investigator_full_name>Rudolf Rosenauer</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <keyword>extracorporeal shock wave</keyword>
  <keyword>microsurgical nerve coaptation</keyword>
  <keyword>nerve regeneration</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Nerve Injuries</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

